Q1 2025 Sun Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Sun Pharmaceuticals Industries Ltd (BOM:524715) reported a 6.3% increase in Q1 FY25 sales compared to Q1 FY24, reaching INR125,245 million.
- The company's EBITDA for Q1 FY25 was INR36,076 million, an 8.3% increase over Q1 FY24, with EBITDA margins improving to 28.5%.
- Net profit after tax for Q1 FY25 was INR28,356 million, up 40.2% over the reported net profit of Q1 last year.
- India business saw a robust growth of 16.4% in sales of formulations, accounting for 33.1% of total consolidated sales.
- Sun Pharmaceuticals Industries Ltd (BOM:524715) launched six new products in India during Q1 FY25, contributing to its market leadership.
- The US business experienced a 1% decline in sales over Q1 last year, with the US accounting for 31.1% of consolidated sales.
- Forex loss for the quarter was INR505 million, compared to a gain of INR20 million in the same period last year.
- Other expenses were at 30.9% of sales, higher year-on-year due to increased R&D and selling and distribution expenses.
- The company faces litigation in the US regarding the launch of Leqselvi, which could delay its market entry.
- Formulation revenues in the rest of the world were down by 2.9% over Q1 FY24, accounting for 12.6% of consolidated Q1 revenue.
Ladies and gentlemen, good day, and welcome to the Q1 FY25 financial results earnings conference call of Sun Pharmaceutical Industries Limited. (Operator Instructions)
I now hand the conference over to Dr. Abhishek Sharma, Vice President, Head Investor Relations and Strategic Projects. Thank you, and over to you, sir.
Thank you. Good evening, and a warm welcome to our first quarter FY25 earnings call. I'm Abhishek from the Sun Pharma Investor Relations team. We hope you have received the Q1 financials and the press release that was sent out earlier in the day. These are also available on our website.
We have with us Mr. Dilip Shanghvi, Chairman and Managing Director, Mr. C.S. Muralidharan, CFO, Mr. Abhay Gandhi, CEO, North America, and Mr.Kirti Ganorkar, CEO, India business.
Today, the team will provide an update on financial performance and business highlights for the quarter, pipeline updates and respond to any questions that you may have. We will refer to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
